A previously healthy man in his 60s developed fever several days after co-habitant family members were diagnosed with COVID-19. He became confused, slowed and forgetful, and tested PCR positive for SARS-CoV-2. Over two weeks his disorientation worsened, he developed paucity of speech with paraphasic errors, and unsteady gait with intermittent right-hand clenching. On admission he was inattentive and perseverative, with non-fluent discourse, anomia, impaired comprehension, phonemic paraphasias, and intermittent myoclonic jerks of the right arm. Laboratory studies revealed abnormal inflammatory markers (summarized in [Table 1](#t0005){ref-type="table"} ). Cerebrospinal fluid (CSF) was acellular, with normal opening pressure, protein, glucose, bacterial culture, IgG and banding pattern, and HSV PCR. CSF and serum autoimmune encephalopathy panels were negative. Electroencephalogram (EEG) revealed abundant 1--1.5 Hz left lateralized periodic discharges and diffuse delta-theta slowing ([Fig. 1](#f0005){ref-type="fig"} ). Brain MRI revealed restricted diffusion ([Fig. 2](#f0010){ref-type="fig"} , A-D) with corresponding FLAIR hyperintensity throughout left hemisphere cortex, and in left caudate nucleus and thalamus. Brain 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) revealed hypometabolism in areas of MRI abnormalities ([Fig. 2](#f0010){ref-type="fig"}, E-F), with crossed right cerebellar diaschisis. He was treated with IVIG and methylprednisolone until CSF RT-QuIC, 14-3-3 and T-tau resulted 2 weeks later confirming the suspicion for Creutzfeldt-Jakob disease (CJD). Neurologic status progressed to mutism, right hemiplegia, spontaneous multifocal myoclonus, somnolence and agitation. He died 2 months after symptom onset.Table 1Abnormal inflammatory markers and reference ranges.Laboratory results:Reference range (units)D-dimer 964\<500 (ng/ml)Ferritin 100220--300 (μg/L)C-Reactive Protein 2.9\<8.0 (mg/L)Erythrocyte Sedimentation Rate 800--13 (mm/hour)Creatine Kinase 4960--400 (U/L)High Sensitivity Troponin T 150--14 (ng/L)Fibrinogen 565150--400 (mg/dL)Lymphocytes 0.791.0--4.8 (K/μL)Fig. 1EEG recording demonstrates frequent 1 Hz left-sided lateralized periodic discharges, with diffuse delta-theta slowing of the background more prominently on the left.Fig. 2A -- D: Brain MRI findings in this case. Diffusion weighted images from A, superior to D, inferior brain regions showing asymmetric restricted diffusion (bright signal, arrows) in the cortical ribbon more prominently in the left hemisphere in prefrontal, posterior parietal and retrosplenial cortices, as well as the insula and cingulate gyrus, with faint signal abnormality also in the body of the caudate nucleus (in C) and pulvinar of thalamus (in D). E-F: 18-FDG PET findings in this case, showing hypometabolism in areas of restricted diffusion.

1. Discussion {#s0005}
=============

Neurological manifestations of COVID-19 include headache, delirium, anosmia, increased stroke risk, dizziness, and encephalitis ([@b9000]). This first report of CJD in a patient with COVID-19 may reflect pure coincidence, given the high, likely underestimated, prevalence of clinically manifest and asymptomatic COVID-19, and the annual incidence of CJD of approximately 1 per million. However, this case raises the specter of a clinically meaningful interaction in which infection with SARS-CoV-2 precipitates or accelerates neurodegenerative diseases.

Animal and human studies of neurodegenerative disease and brain injury show that release of pro-inflammatory cytokines -- IL-1, IL-6, IL-12, and TNFα by activated microglia or reactive A1-astrocytes in the course of a systemic immune response promote neuroinflammation and may accelerate disease progression in Alzheimer disease ([@b9005]), Parkinson disease ([@b9010]), multiple system atrophy ([@b9020]), frontotemporal dementia ([@b9015]), progressive supranuclear palsy, primary progressive aphasia, and stroke ([@b0025]). Fast neurodegeneration is associated with elevation of plasma IL-13, TNF- α and G-CSF in rapidly progressive AD ([@b0050]).

CJD is caused by the accumulation of abnormally folded, protease-resistant isoforms of host cellular sialoglycoproteins (i.e., prion proteins). Accumulation predominantly of prion protein scrapie, PrPSc, leads to vacuolation and spongiform neuropathologic changes coinciding with rapid neurodegeneration and activation of astrocytes and microglia in affected regions. Animal studies demonstrate accelerated transition from pre-clinical to clinical stages of prion disease in settings of co-infection. Mice co-infected with *T. muris* after direct CNS PrPSc injections developed a polarized immune response with increased CD8+ T cell recruitment, and elevated levels of pro-inflammatory cytokines including IFN-γ, and enhanced activation of A1 reactive astrocytes that significantly shortened time to development of clinical signs ([@b0010]).

Depending on local milieu, astrocytes may be induced to assume one of two distinct reactive forms: a neurotoxic A1 phenotype and a neuroprotective A2 phenotype. A1 astrocytes potentiate death of neighboring neurons and oligodendrogliocytes ([@b0030]). Il-1, TNF and C1q are collectively necessary and sufficient for A1 astrocyte activation ([@b0030]). In prion disease, A1 reactive astrocytes are thought to be neurotoxic by mediating neuronal damage of adjacent neuronal processes and serving as foci for PrPSc propagation ([@b0035]). Pre-clinical CJD is marked by retention of region-specific homeostatic identities of glia, including astrocytes. During the transition to clinical CJD these region-specific signatures are lost and replaced by a neuroinflammatory transcriptome signature that affects astrocyte sub-populations in a region-dependent manner ([@b0035]).

The simultaneous clinical presentations of COVID-19 and CJD in this patient led us to hypothesize that the cascade of systemic inflammatory mediators that characterize COVID-19 may have accelerated the prion disease pathogenesis and neurodegeneration by facilitating loss of region-specific homeostatic identities of astrocytes and fostering a neuroinflammatory transcriptional signature. The molecular mechanism remains to be determined, but there is empirical support for our hypothesis in that there is inflammasome activation and increased secretion of Il-1 ([@b0005]), TNF and complement cascade in COVID-19 ([@b0040]), and the fact that Il-1, TNF and C1q are necessary and sufficient for activation of A1 astrocytes ([@b0030]) which affect prion propagation.

Lateralized presentation of CJD has been reported previously. Notably, lateralized modulation of immune function ([@b0045]) and inter-hemispheric asymmetry in basal levels of cytokines and distribution of microglia are documented ([@b0020]), perhaps predisposing to asymmetric prion disease propagation and neurodegeneration, and compounded by systemic inflammatory responses.

Neurological dysfunction in COVID-19 is likely caused by immune responses systemically and within the nervous system ([@b0015]). Our hypothesis that inflammatory responses to SARS-Cov-2 precipitate or exacerbate neurodegenerative disease is urgent because COVID-19 portends disproportionately worse outcomes in the elderly who are already at risk of neurodegenerative disease.
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